semaj83/ctmatch_classification huggingface dataset:
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Malaria Plasmodium Falciparum Age > 18 and < 35 years healthy volunteers (males or females) Good health based on history and clinical examination Negative pregnancy test Use of adequate contraception for females Signing of the informed consent form, thereby demonstrating understanding of the meaning and procedures of the study Agreement to inform the general practitioner and to sign a request to release medical information concerning contra-indications for participation in the study Willingness to undergo a Pf controlled infection through mosquito bites Agreement to stay in a hotel room close to the trial center during a part of the study (Day 5 after challenge till treatment is finished) Reachable (24/7) by mobile phone during the whole study period Available to attend all study visits  History of malaria Plans to travel to malaria endemic areas during the study period Plans to travel outside of the Netherlands during the challenge period Previous participation in any malaria vaccine study and/or positive serology for Pf Symptoms, physical signs and laboratory values suggestive of systemic disorders including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, and other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteers History of diabetes mellitus or cancer (except basal cell carcinoma of the skin) History of arrhythmias or prolonged QT-interval Positive family history in 1st and 2nd degree relatives for cardiac events < 50 years old An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system Clinically significant abnormalities in electrocardiogram (ECG) at screening
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Vivax Malaria Age 18-50 years Gestational age (ultrasound confirmed) > 13.0 weeks Viable fetus as assessed by ultrasound scanning Microscopically confirmed uncomplicated P.vivax malaria Willingness and ability to comply with the study protocol for the duration of the trial Written informed consent provided No signs of labour  Known hypersensitivity to chloroquine Clinical or laboratory features of severe malaria based on WHO criteria-Appendix 1 Gastrointestinal dysfunction that could alter absorption or motility History or known liver diseases or other chronic diseases (excluding thalassaemia & G6PD deficiency) Presence of intercurrent illness or any condition which in the judgement of the investigator would place the patient at undue risk or interfere with the results of the study Splenectomy Hematocrit (HCT) < 20% (based on field reading i.e. capillary sample) Taking contraindicated medications History of narcotic or alcohol abuse
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Immune Reconstitution Inflammatory Syndrome Opportunistic Infections Age > 18 years Informed consent ART naive  No informed consent History of ART use Pregnancy
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Malaria Plasmodium Falciparum Healthy volunteers (males or females) of ≥ 18 and ≤ 35 years of age Good health based on history and clinical examination (physical examination and laboratory screening) Negative pregnancy test Use of adequate contraception for females Signing of the informed consent form, thereby demonstrating understanding of the meaning and procedures of the study Agreement to inform the general practitioner and to sign a request to release medical information concerning contraindications for participation in the study Willingness to undergo administration of PfSPZ Challenge by needle and syringe and willingness to undergo challenge by mosquito bites For volunteers not living in Nijmegen: agreement to stay in a hotel room close to the trial centre or living in Nijmegen with a third party that could contact the clinicians in case of alteration of consciousness during a part of the study (day 5 after challenge until treatment is finished) Reachable (24/7) by mobile phone during the whole study period For volunteers living in Nijmegen: living with a third party that could contact the clinicians in case of alteration of consciousness or agreement to stay in a hotel room close to the trial centre during a part of the study (day 5 after challenge until treatment is finished)  History of malaria Plans to travel to malaria endemic areas during the study period Plans to travel outside of the Netherlands during the challenge period Previous participation in any malaria vaccine study and/or positive serology for Pf Symptoms, physical signs and laboratory values suggestive of systemic disorders including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, and other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteers History of diabetes mellitus or cancer (except basal cell carcinoma of the skin) History of arrhythmias or prolonged QT-interval Positive family history of 1st and/or 2nd degree relatives who experienced cardiac events when < 50 years old An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system Clinically significant abnormalities in electrocardiogram (ECG) at screening
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Venous Thromboembolic Disease Deep Vein Thrombosis Pulmonary Embolism Admitted to Scripps Mercy Trauma Service ≥18 Years old Stratified to either Significant or Highest risk of VTE by ACCP guidelines  Estimated Injury Severity Score (ISS) ≤9 Likely to be discharged before hospital day 7 Systemic coagulopathy (International Normalized Ratio [INR] of ≥1.2) Body Mass Index (BMI) >40 Likely to Survive for <7 Days Pregnancy Evidence of renal insufficiency (Cr ≥1.3) Delayed transfer to this facility (>24 hrs) Prisoners
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Malaria in Pregnancy HIV Infection age ≥ 18 years HIV positivity gestational age between 16 and 28 weeks CD4+ count > 350 cells/mm3 and no sign of WHO stage 2, 3 or 4 agreement to attend all the antenatal consultations for the study willingness to adhere to all requirements of the study (including HIV-1 voluntary counseling and testing) signed informed consent  psychological instability that could interfere with compliance hypersensitivity to sulfamides or dermatological disease(eczema, pemphigoid exanthema) that would increase the risk for severe reactions to the drugs being tested severe anaemia (Hb<7 g/dl)and any other severe disease known hepatic cardiac or renal disease
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 5.0-65.0,  Malaria, Falciparum Age between 5 and 65 years old inclusive Monoinfection of P. falciparum confirmed by microscopy Documented fever (axillary temperature > 37.5°C) and/or history of fever during the previous 48 hours in the absence of other obvious causes of fever (such as pneumonia, otitis media, etc) Infection with P. falciparum of 1000 and 100,000 asexual parasites per microliter (μl) to be determined by microscopic examination of a thick or thin smear, and positive confirmation by polymerase chain reaction (PCR); * Presence of sexual form of P. vivax is acceptable; ** PCR confirmation is not an enrollment requirement Informed consent must be obtained from the participant or both parents/guardian (in the case of children), and assent from the child (from 8 to 17 years old) Willingness of the participant to return to the health facility for regular check-ups during the follow-up period of 42 days Willingness of the participant to transfer to the Hospital de Apoyo Iquitos to start treatment  Severe malaria signs (as defined by the World Health Organization) Cerebral malaria (irreversible coma) Severe anemia (hematocrit < 15%, or clinic signs) Clinic signs of kidney failure (e.g., serum creatinine > 3 mg/dL) Pulmonary edema Hypoglycemia (glucose in the blood <40mg/dL or clinic signs) Shock (PA systolic < 70 mm Hg in adults; < 50 in children) Spontaneous bleeding/Disseminated intravascular coagulation (CID) Recurrent generalized convulsions Acidemia/acidosis (clinic signs)
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Travelers' Diarrhea Functional Bowel Disorders Reactive Arthritis An Institutional Review Board (IRB) / Ethics Committee (EC)-approved informed consent form is signed and dated Subject is at least 18 years of age Subject's duration of prophylaxis will be least 2 weeks Subject is capable of and willing to comply with all study procedures and available for the end of study visits and sample collection at COO (within 6 months from start of prophylaxis) Women: Non-nursing and negative urine/serum pregnancy test with understanding (through informed consent process) to avoid pregnancy while on study drug. Sole reliance on oral contraceptives (OCPs) for birth control will not be recommended (see section 6.3.2.1.) Should an individual have a documented surgical sterilization in her medical record, a pregnancy test will not be required. If a volunteer becomes pregnant during the study, the principal investigator will notify the study research monitor and the IRBs. The pregnancy outcome will be followed per IRB and other regulatory requirements for US and UK personnel (For US Personnel Only). Have consented to participate in TravMil protocol  Subject received any systemic or gastrointestinal antibiotic in the 7 days prior to enrollment (except anti-malarial prophylaxis agents) Subject has hypersensitivity or allergy to rifaximin or rifampicin Subject has acute diarrhea within 7 days prior to enrollment Subject has a concomitant disease or condition that could interfere with, or for which treatment could interfere with, the conduct of the study, or could in the opinion of the investigator increase the risk of AEs during the subject's participation in the study Subject is currently taking or plans to take during deployment at least one of the following medications: theophylline or warfarin (Coumadin)
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Malaria All of the following must be fulfilled for a subject to participate in this trial Age greater than or equal to 18 and less than or equal to 50 years In good general health and without clinically significant medical history Malaria comprehension exam completed, passed (a score of greater than or equal to 80% or per investigator s discretion) and reviewed prior to enrollment Reliable access to the clinical trial center and availability to participate for duration of study Females of childbearing potential must be willing to use reliable contraception (as defined below) from 21 days prior to study day -2 to 28 days following last Sanaria  Subject to the judgment and discretion of the PI, female participants who meet ANY ONE of the listed immediately below, may not be required to take any additional measures to avoid pregnancy. Such participants will be counseled on risks at the time of consent and at appropriate points (e.g. when pregnancy testing occurs) during the study Females who have had their uterus, and/or BOTH ovaries removed Females who have had BOTH fallopian tubes surgically tied or removed Females who are above the age of 45 and have spontaneously had no menses at any point during the past 12 or more consecutive months (i.e. have reached menopause)  A subject will be excluded from participating in this trial if any one of the following is fulfilled Currently is breast-feeding (if female) Pregnancy as determined by a positive urine or serum human choriogonadotropin (beta-hCG) test at any point during the study (if female) Recent travel to a malaria endemic area within 5 years of enrollment Planned travel to a malaria endemic area during the study period History of confirmed malaria diagnosis on peripheral blood smear or by clinical history in the past 10 years Hemoglobin, WBC, platelets, ALT, and creatinine outside of local lab normal range (subjects may be included at the investigator s discretion for not clinically significant values outside of normal range) Abnormal urinalysis as defined by positive urine glucose, protein, and hemoglobin. Subject can be included if investigator determine the abnormality is not clinically significant  Anticipated use during the study period, or use within the following periods prior to enrollment Investigational malaria vaccine within the last five years
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 0.833-3.167,  Neurobehavioral Manifestations Enrolled in Makerere University-UCSF II study HIV-uninfected 12 months of age at the time of enrollment Within 30 km of the clinic  Serious adverse event to the study drugs requiring cessation of study drug Active illness at enrollment (child can be enrolled once active illness has been treated and they are back to baseline health) Previous history of head trauma or coma in the child Cerebral palsy or other severe neurologic disease Known chronic illness requiring medical care Major medical abnormalities on screening history of past health Known developmental delay
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Rabies Provide signed and dated informed consent form Willing to comply with all study procedures and be available for the duration of the study Male or female, aged ≥ 18 to ≤ 60 years on day of inclusion In good general health based on medical history and physical exam  Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination and until at least 4 weeks after the last vaccination Participation in the 4 weeks preceding the first trial vaccination, or planned participation during the present trial period, in another clinical trial investigating a vaccine, drug, medical device, or medical procedure Previous history of receiving the rabies vaccine Previous history of receiving rabies immune globulin Any major psychiatric disorder, such as severe depression, severe anxiety disorder, psychosis, schizophrenia, other major psychiatric disorders, or seizures. History of mild depression or anxiety disorder that are well controlled are not criteria Use of any immunosuppressive drug at the time of the study or 30 days previously. Topical steroids will not be considered an immunosuppressive drug and their use will not be considered an Any immunosuppressive disorder, such as HIV infection, common variable immunodeficiency, active cancers or chemotherapy History of renal insufficiency or requiring dialysis Have any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol Identified as an employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employee or the Investigator
Patient description: A 21-year-old college student undergoes colonoscopy due to family history of multiple polyps in his older siblings. His brother underwent total proctocolectomy at age 22, and his sister underwent a total proctocolectomy at age 28, after both were found to have hundreds of colonic adenomas on colonoscopy. Both siblings are currently well without any findings of neoplasms. The patient undergoes sigmoidoscopy and is found to have dozens of small colonic polyps within rectosigmoid. Several of these are biopsied and are all benign adenomas.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Colorectal Cancer Small Intestine Cancer One of the following diagnosis Diagnosis of familial adenomatous polyposis Prior total or subtotal colectomy Attenuated adenomatous polyposis coli May have colon intact 40 duodenal polyps from second portion to 10 cm distal to papilla of Vater Age to 80 Performance status Not specified
Patient description: A 21-year-old college student undergoes colonoscopy due to family history of multiple polyps in his older siblings. His brother underwent total proctocolectomy at age 22, and his sister underwent a total proctocolectomy at age 28, after both were found to have hundreds of colonic adenomas on colonoscopy. Both siblings are currently well without any findings of neoplasms. The patient undergoes sigmoidoscopy and is found to have dozens of small colonic polyps within rectosigmoid. Several of these are biopsied and are all benign adenomas.

Clinical trial eligibility criteria: eligible ages (years): 0.0-70.0,  Colorectal Cancer Diagnosis of colon cancer or polyps at age 70 or under Has a living full sibling with diagnosis of colon cancer or polyps at age 70 or under No history of familial adenomatous polyposis syndrome No hereditary nonpolyposis colon cancer, according to Amsterdam No known I1370K adenomatous polyposis of the colon susceptibility variant Enrolled on 1 of the following clinical trials CLB-9581 CLB-89803 CLB-80001 NOTE: Patients do not need to be receiving protocol therapy. Patients who are outside the treatment protocol's follow-up range are eligible. Patients who discontinued therapy for any reason, including toxic effects, are eligible Age
Patient description: A 21-year-old college student undergoes colonoscopy due to family history of multiple polyps in his older siblings. His brother underwent total proctocolectomy at age 22, and his sister underwent a total proctocolectomy at age 28, after both were found to have hundreds of colonic adenomas on colonoscopy. Both siblings are currently well without any findings of neoplasms. The patient undergoes sigmoidoscopy and is found to have dozens of small colonic polyps within rectosigmoid. Several of these are biopsied and are all benign adenomas.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Adenomatous Polyposis Coli Males or females at least 18 years of age with familial adenomatous polyposis
Patient description: A 21-year-old college student undergoes colonoscopy due to family history of multiple polyps in his older siblings. His brother underwent total proctocolectomy at age 22, and his sister underwent a total proctocolectomy at age 28, after both were found to have hundreds of colonic adenomas on colonoscopy. Both siblings are currently well without any findings of neoplasms. The patient undergoes sigmoidoscopy and is found to have dozens of small colonic polyps within rectosigmoid. Several of these are biopsied and are all benign adenomas.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Colon Adenomas Patients are aged between 18 and 75 years At least 3 adenomas irrespective size or at least one measuring 6mm or more All subjects had a clean colon at the study entry  No personal history of colon cancer, no inflammatory bowel disease, no familial adenomatous polyposis, no regular use of aspirin
Patient description: A 21-year-old college student undergoes colonoscopy due to family history of multiple polyps in his older siblings. His brother underwent total proctocolectomy at age 22, and his sister underwent a total proctocolectomy at age 28, after both were found to have hundreds of colonic adenomas on colonoscopy. Both siblings are currently well without any findings of neoplasms. The patient undergoes sigmoidoscopy and is found to have dozens of small colonic polyps within rectosigmoid. Several of these are biopsied and are all benign adenomas.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Familial Adenomatous Polyposis Patients with Familial adenomatous polyposis who have had ileo-rectal anastomosis and had 20 or less adenomas at previous surveillance examination  poor bowel preparation, unable or unwilling to give informed consent, under 18 years of age,those with more than 20 adenoma